Combination therapy consisting of once-daily macitentan and tadalafil was associated with reductions in pulmonary vascular resistance in patients with pulmonary arterial hypertension. NEW ORLEANS – ...

FDA approved macitentan/tadalafil (Opsynvi) as the first single-tablet combination therapy targeting multiple pathways for pulmonary arterial hypertension (PAH), Johnson & Johnson announced. The fixed ...

Patients with pulmonary arterial hypertension (PAH) taking spironolactone saw a reduced risk of morbidity and mortality when receiving macitentan 10 mg. Research presented at CHEST 2021 showed that ...

REPAIR study findings outline the benefits of macitentan for right ventricular functioning in pulmonary arterial hypertension. Results of the REPAIR (Right vEntricular remodeling in Pulmonary ArterIal ...

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension. SAN ANTONIO — In patients with ...

Actelion Pharmaceuticals Ltd / Actelion's macitentan meets primary endpoint in pivotal Phase III SERAPHIN outcome study in patients with pulmonary arterial hypertension . Processed and transmitted by ...

ATLANTA — Macitentan significantly reduced morbidity and mortality in patients with pulmonary arterial hypertension (PAH), according to findings from the phase 3 SERAPHIN trial. Lewis Rubin, MD, from ...

In an oral presentation, Dr Nazzareno Galiè from the Institute of Cardiology, University of Bologna, Bologna, Italy presented data evaluating the association between 6MWD, a measure of exercise ...

Please provide your email address to receive an email when new articles are posted on . Macitentan showed no new safety signals in patients with pulmonary arterial hypertension from two real-world ...

The study found no significant differences between the groups in terms of disease progression, morbidity or mortality, or all-cause death. Macitentan demonstrated superiority over other endothelin ...

Please provide your email address to receive an email when new articles are posted on . Treatment with a 10-mg dose of macitentan significantly decreased the risk for and prevalence of all-cause ...

Macitentan significantly reduced the risk of morbidity and mortality by 45% versus placebo Macitentan reduced the risk of PAH-related death or hospitalization by 50% The presentation from Professor ...